Remedy Pharmaceuticals Appoints Thomas MacAllister as Vice President of Research and Development and General Counsel

NEW YORK–(BUSINESS WIRE)– Remedy Pharmaceuticals, a privately-held, Phase 3-ready pharmaceutical
company focused on bringing life-saving hospital-based treatment to
people affected by central nervous system (CNS) related edema, today
announced that the Company appointed Thomas MacAllister as Vice
President of Research and Development, and General Counsel.

“As we begin preparations for commencement later this year of our Phase
3 clinical trial in patients with large hemispheric stroke, Tom’s wealth
of CNS-related clinical trial experience will be indispensable,” states
Sven Jacobson, CEO of Remedy Pharmaceuticals. “We’re therefore delighted
to welcome him to the senior management team.”

Thomas MacAllister, Ph.D., JD, has over 25 years of experience in
business development, preclinical and clinical development, regulatory
strategy, intellectual property and commercialization. He has assembled
and led a team that took a program for severe traumatic brain injury
from concept through the completion of a Phase 3 clinical trial. Prior
to joining Remedy Pharmaceuticals, Dr. MacAllister served as the Chief
Executive Officer of Argentum Pharmaceuticals, for whom he developed new
business models to reduce the cost of drugs to the healthcare system. He
also served as Chief Executive Officer and General Counsel at BHR Pharma
and Chief Development Officer at Besins Healthcare SA where he was
primarily focused on drug development and oversaw research and
development and the intellectual property department. He is an attorney
licensed to practice law in the Commonwealth of Virginia, the District
of Columbia and before the United States Patent & Trademark Office.

“I am excited to join the Remedy Pharmaceuticals at this pivotal time,”
notes Thomas MacAllister. “I believe that the Company’s lead product,
CIRARA, represents a significant opportunity to define the treatment of
CNS-related edema, and thus save and improve the lives of countless
patients for whom there are currently no effective therapies. I look
forward to helping advance this novel compound through clinical
development.”

ABOUT CIRARA™

CIRARA™ is a patented, high affinity inhibitor of Sur1-Trpm4 channels,
discovered by University of Maryland neurosurgeon Dr. J. Marc Simard.
CIRARA is suitable for intravenous delivery at the bedside or even in an
ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA
is an investigational drug and is not approved by FDA.

ABOUT REMEDY PHARMACEUTICALS

Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage
pharmaceutical company focused on developing and bringing lifesaving
treatment to millions of people affected by acute central nervous system
(CNS) edema – including stroke, traumatic brain injury, spinal cord
injury, as well as other ischemic injuries and neurological disorders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160315005038/en/